Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market ...
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...
StockStory.org on MSN1d
PacBio (NASDAQ:PACB) Misses Q4 Sales TargetsDetailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...
Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...
After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...
Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback